✦ LIBER ✦

Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

✍ Scribed by Conconi, Annarita; Raderer, Markus; Franceschetti, Silvia; Devizzi, Liliana; Ferreri, Andrés J. M.; Magagnoli, Massimo; Arcaini, Luca; Zinzani, Pier Luigi; Martinelli, Giovanni; Vitolo, Umberto; Kiesewetter, Barbara; Porro, Elena; Stathis, Anastasios; Gaidano, Gianluca; Cavalli, Franco; Zucca, Emanuele

Book ID: 121683627
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 109 KB
Volume: 166
Category: Article
ISSN: 0007-1048
DOI: 10.1111/bjh.12845

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I/II Study of a Hybrid Schedule

A Phase I/II Study of a Hybrid Schedule of Flavopiridol in Relapsed/Refractory Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

✍ Kieron Dunleavy; Geoff Shapiro; Megan Disinski; Lucian Chirieac; Stefania Pittal 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 47 KB

Six-month oral clarithromycin regimen is

Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial

✍ Silvia Govi; Giuseppina P. Dognini; Giada Licata; Roberto Crocchiolo; Antonio Gi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB

Phase II study of Amsacrine in refractor

Phase II study of Amsacrine in refractory lymphomas. A report of the EORTC early clinical trials group

✍ Bramwell, Vivien H.C.; Holdener, E.E.; Siegenthaler, P.; Ten Bokkel Huinink, W.; 📂 Article 📅 1984 🏛 Elsevier Science ⚖ 683 KB

Waldeyer’s ring marginal zone B cell lym

Waldeyer’s ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL)

✍ Sung Yong Oh, Won Seog Kim, Jin Seok Kim… 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 246 KB

Brentuximab Vedotin (SGN-35) in Patients

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

✍ Pro, B.; Advani, R.; Brice, P.; Bartlett, N. L.; Rosenblatt, J. D.; Illidge, T.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 395 KB

IDEC-C2B8 (Rituximab) anti-CD20 antibody

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

✍ M. Feuring-Buske; M. Kneba; M. Unterhalt; A. Engert; M. Gramatzki; E. Hiller; L. 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 90 KB